Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push
[ad_1]
Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business.
[ad_2]
Source link
[ad_1]
Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business.
[ad_2]
Source link
